NCCN 2019 Nursing Forum: Oncology Nursing in Hematologic Malignancies

San Francisco, CA US
September 27, 2019

The NCCN 2019 Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™ will provide hematology/oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information is focused on current and critical issues to provide hematology/oncology nurses with practical information that can be implemented in the practice setting.

Registration

Agenda

Fees

Target Audience

This educational program is designed to meet the educational needs of hematology/oncology nurses and nurse practitioners who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Evaluate advances in the management of patients with hematologic malignancies and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
  • Review issues related to toxicities and adverse events associated with CAR T-cell therapy, infection, tumor lysis syndrome, and bone health, and implement appropriate strategies for managing these in the health care setting.

Session Learning Objectives

Prevention of Infection in Patients with Hematologic Malignancies

  • Recognize the risk for infection in patients with hematologic malignancies.
  • Describe the presentation of infections in patients with hematologic malignancies.
  • Discuss strategies for the prevention of infection in patients with hematologic malignancies.

Management of Bone Health in Patients with Multiple Myeloma

  • Recognize disease-related and treatment-related bone complications in patients with multiple myeloma (MM).
  • Identify the adverse effects associated with bone-modifying agents.
  • Outline strategies for prevention and management of bone-disease to optimize patient outcomes.

Updates in the Management of Tumor Lysis Syndrome

  • Identify the risk factors associated with the development of tumor lysis syndrome (TLS).
  • Outline the indications for anti-hyperuricemic agents used for the management of TLS.
  • Develop strategies for the management of TLS based on risk assessment, underlying malignancy and type of therapy administered.

Management of Toxicities Related to CAR T-Cell Therapy

  • Understand the scope and presentation of CAR T-cell therapy–related toxicity.
  • Assess patients receiving CAR T-cell therapy for potential adverse events.
  • Understand how to apply the NCCN Guidelines for managing adverse events associated with CAR T-cell therapy.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Celgene Corporation
  • Coherus Biosciences
  • Pfizer Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Available credit: 
  • 2.60 ANCC contact hours
  • 2.60 Participation
Course opens: 
09/25/2019
Course expires: 
12/15/2019
Event starts: 
09/27/2019 - 2:00pm
Event ends: 
09/27/2019 - 5:15pm
Cost:
$0.00
Hilton San Francisco Union Square
333 O'Farrell Street
Imperial Ballroom
San Francisco, CA 94102
United States

NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses no relevant financial relationships:

Colleen H. Erb, MSN, CRNP, ACNP-BC, AOCNP
Yi Lisa Hwa, APRN, CNP, DNP
Lauren Spendley, MSN, AGNP-BC, AOCN

The faculty listed below discloses the following relevant financial relationships:

Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Salix Pharmaceuticals: Consulting Fee
Stemline Therapeutics: Consulting Fee

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Sarah Sinclair; Kathy Ann Smith, CHCP; Gary J. Weyhmuller, MBA, SPHR

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Mary A. Dwyer, MS, CGC; Alyse Johnson-Chilla, MS; Rashmi Kumar, PhD; Hema Sundar, PhD

The NCCN Clinical staff listed below discloses the following relevant financial relationships:

Griselda Zuccarino-Catania, PhD
Janssen Pharmaceutica Products, LP: Salary (Spouse)

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this educational activity for a maximum of 2.6 contact hours.

Available Credit

  • 2.60 ANCC contact hours
  • 2.60 Participation

Accreditation Period

Course opens: 
09/25/2019
Course expires: 
12/15/2019

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing